Search clinical trials for: Proellex 12 mg

Total 11355 results

Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Repros Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Uterine Fibroids
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
Repros Therapeutics Inc.

Completed

Proellex Pharmacokinetics Bridging Study

Healthy

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

Mexico
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Vaginal Administration

Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules

United States
Repros Therapeutics Inc.

Terminated

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States, Mexico
Repros Therapeutics Inc.

Completed

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Impaired Liver Function

United States
Repros Therapeutics Inc.

Withdrawn

Open-Label Extension Study to ZPE-202

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Crossover Study of the Safety and PK Properties of Proellex®

Pharmacokinetics

United States
Repros Therapeutics Inc.

Completed

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

ABSORPTION | METABOLISM | EXCRETION

United States
Repros Therapeutics Inc.

Withdrawn

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Uterine Fibroids

United States, Brazil
University of Aarhus
Aarhus University Hospital

Completed

Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)

Obesity, Abdominal

Denmark
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

A Safety and Pharmacokinetic Study of Proellex® (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Alzheimer Disease
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Serpin Pharma, LLC
University of Virginia

Recruiting

SP16 as a Therapeutic for COVID-19 Induced ARDS

Pneumonia | SARS CoV 2 Infection

United States
Repros Therapeutics Inc.

Terminated

Study to Evaluate Menses Induction in Women Administered Proellex

Amenorrhea

United States
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Repros Therapeutics Inc.

Completed

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Otonomy, Inc.

Completed

OTO-104 for Meniere's Disease

Meniere's Disease

United States
University of Texas Southwestern Medical Center
GlaxoSmithKline

Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
Watson Pharmaceuticals

Completed

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Repros Therapeutics Inc.

Terminated

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Endometriosis

United States
Janssen Research & Development, LLC

Completed

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous

France, United Kingdom, Spain, Portugal, United States, Germany
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
Repros Therapeutics Inc.

Completed

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Uterine Fibroids

United States
Fundacion para la Investigacion Biomedica del Hospital...

Completed

Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis

Cystic Fibrosis

Spain
Ardea Biosciences, Inc.

Completed

RDEA3170 PK/PD Study

Gout

United States
Repros Therapeutics Inc.

Completed

Determination of the Lowest, Safe and Effective Dose of Proellex

Amenorrhea

United States
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Mundipharma Research Limited

Completed

A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.

Pain

United Kingdom
Estetra

Completed

E4/DRSP Single and Multiple Dose PK and Early QT Study

Contraception
Northwestern University
National Cancer Institute (NCI)

Completed

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Stage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease

3

Subscribe